Oncology sales drive AstraZeneca’s Q4 Earnings
AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter.
Read More
Tag: earnings
GSK posts Q4 profit
GlaxoSmithKline (GSK) has released its fourth-quarter 2018 results, reporting prescription drug sales of £4.8 billion – a 6% increase on the prior year period – and profit of £1.4 billion, marking an increase of £442 million.
Read More
AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
Read More
GSK narrows earnings guidance after Shingrix boost
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic competition for one of its key products.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
